György Bodoky
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Gargiulo P, Pignata S, Berardi S, Glimelius B, Scheithauer W, Ruhstaller T, Bodoky G, Herrmann R, Dietrich D, Brauchli P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Ther Adv Med Oncol 2019; 11:1758835918818351.
02.01.2019Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
02.01.2019Ther Adv Med Oncol 2019; 11:1758835918818351
Gargiulo Piera, Pignata Sandro, Berardi Simona, Glimelius Bengt, Scheithauer Werner, Ruhstaller Thomas, Bodoky György, Herrmann Richard, Dietrich Daniel, Brauchli Peter
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
von Moos R, Plasswilm L, Zwahlen D, Meier U, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K, Saletti P, Rauch D, Koeberle D, Schacher S, Hayoz S, Winterhalder R, Roth A, Bodoky G, Samaras P, Berger M, Swiss Group for Clinical Cancer Research (SAKK). Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08). Eur J Cancer 2017; 89:82-89.
11.12.2017Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08)
11.12.2017Eur J Cancer 2017; 89:82-89
von Moos Roger, Plasswilm Ludwig, Zwahlen Daniel, Meier Urs R, Yan Pu, Izzo Paola, Klingbiel Dirk, Bärtschi Daniela, Zaugg Kathrin, Saletti Piercarlo, Rauch Daniel, Koeberle Dieter, Schacher Sabina, Hayoz Stefanie, Winterhalder Ralph C, Roth Arnaud, Bodoky György, Samaras Panagiotis, Berger Martin D, Swiss Group for Clinical Cancer Research (SAKK)
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
Bernhard J, Pestalozzi B, Köhne C, Mingrone W, Stemmer S, Tàmas K, Kornek G, Koeberle D, Herrmann R, Figer A, Bauer J, Saletti P, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Central European Cooperative Oncology Group. Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701.
01.08.2008Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001
01.08.2008Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008; 26:3695-701
Bernhard Jürg, Pestalozzi Bernhard C, Köhne Claus-Henning, Mingrone Walter, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Koeberle Dieter, Herrmann Richard, Figer Arie, Bauer Jean, Saletti Piercarlo, Dietrich Daniel, Scheithauer Werner, Gerber Daniela, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Central European Cooperative Oncology Group
CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
Hess V, Scheithauer W, Figer A, Saletti P, Bajetta E, Ruhstaller T, Bodoky G, Dietrich D, Grawe P, Glimelius B, Herrmann R. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. The lancet oncology 2008; 9:132-8.
01.02.2008CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial
01.02.2008The lancet oncology 2008; 9:132-8
Hess Viviane, Scheithauer Werner, Figer Arie, Saletti Piercarlo, Bajetta Emilio, Ruhstaller Thomas, Bodoky György, Dietrich Daniel, Grawe Philipp, Glimelius Bengt, Herrmann Richard
Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
Herrmann R, Stemmer S, Tàmas K, Kornek G, Köberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W, Swiss Group for Clinical Cancer Research, Mingrone W, Köhne C, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Central European Cooperative Oncology Group. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7.
01.06.2007Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
01.06.2007Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007; 25:2212-7
Herrmann Richard, Stemmer Salomon M, Tàmas Karin, Kornek Gabriela V, Köberle Dieter, Cina Susanne, Bernhard Jürg, Dietrich Daniel, Scheithauer Werner, Swiss Group for Clinical Cancer Research, Mingrone Walter, Köhne Claus-Henning, Bodoky György, Ruhstaller Thomas, Glimelius Bengt, Bajetta Emilio, Schüller Johannes, Saletti Piercarlo, Bauer Jean, Figer Arie, Pestalozzi Bernhard, Central European Cooperative Oncology Group